# A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

> **NCT05818709** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 61 (actual)

## Conditions studied

- Facial Volume Deficit

## Interventions

- **DEVICE:** HAC 22L

## Key facts

- **NCT ID:** NCT05818709
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-14
- **Primary completion:** 2025-12-05
- **Final completion:** 2025-12-05
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05818709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05818709, "A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05818709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*